Article Figures & Data
Figures
- FIGURE 1.
A 64-y-old healthy female volunteer. Maximum-intensity-projection PET images of 7 sequential WB images from 0 to 240 min after injection of 316 MBq of 18F-FSPG.
- FIGURE 2.
Mean time–activity curves for selected organs (kidneys, liver, pancreas, and stomach wall) (A) and urinary bladder (B) after injection of 18F-FSPG in 5 healthy volunteers. Volunteers emptied their bladders after 0.75 and 3.0 h. Variability represented by error bars.
- FIGURE 3.
Time–activity curve in whole-blood samples (A) and in plasma samples (B). Measured data in 4 subjects; blood sampling for metabolite analysis was not performed in 1 subject.
- FIGURE 4.
Thin-layer chromatography results in plasma (n = 4). Only intact tracer was detected.
Tables
Subject no. Sex Age (y) Specific activity (GBq/μmol) Injected dose (MBq) 1101 F 58 361 283 1102 F 64 269 316 1103 M 57 199 275 1104 F 63 282 330 1105 M 51 433 295 Mean ± SD 58.6 ± 5.2 309 ± 90 300 ± 22.9 Scan Time (min) Axial extent of scan Scan duration Low-dose CT −2 Total body 1 0 Total body 1 min per bed position 2 12 WB 1 min per bed position 3 19 WB 1 min per bed position 4 26 WB 1 min per bed position 5 33 WB 1 min per bed position Ultra-low-dose CT 149 WB 6 150 WB 4 min per bed position Ultra-low-dose CT 239 WB 7 240 WB 4 min per bed position Ultra-low-dose CT was performed when subject was repositioned on scanner after getting up for bladder voiding.
- TABLE 3
Absorbed Dose Estimates (in mSv/MBq): Mean Values for 5 Subjects for Bladder-Voiding Time of 3.5 Hours
Organ Mean Adrenals 0.0094 Brain 0.0030 Breasts 0.0033 Gallbladder wall 0.0089 Lower large intestine wall 0.016 Small intestine 0.0097 Stomach wall 0.017 Upper large intestine wall 0.0087 Heart wall 0.011 Kidneys 0.11 Liver 0.014 Lungs 0.0045 Muscle 0.0069 Ovaries 0.015 Pancreas 0.077 Red marrow 0.0086 Osteogenic cells 0.0081 Salivary glands 0.0064 Skin 0.0040 Spleen 0.015 Testes 0.011 Thymus 0.0043 Thyroid 0.013 Urinary bladder wall 0.40 Uterus 0.030 Total body 0.0076 ED 0.032 Tracer ED (mSv/MBq) 18F-FSPG 0.032 ± 0.0034 18F-FDG (15) 0.019 3′-deoxy-3′-18F-fluorothymidine (16) 0.028 ± 0.012 O-(2-18F-fluoroethyl)-l-tyrosine (17) 0.016 18F-fluoromethylcholine (18) 0.031 ± 0.007
Jump to section
Related Articles
Cited By...
- Clinical Characterization of [18F]T-008, a Cholesterol 24-Hydroxylase PET Ligand: Dosimetry, Kinetic Modeling, Variability, and Soticlestat Occupancy
- PET Imaging of System xC- in Immune Cells for Assessment of Disease Activity in Mice and Patients with Inflammatory Bowel Disease
- First-in-Human PET Imaging and Estimated Radiation Dosimetry of L-[5-11C]-Glutamine in Patients with Metastatic Colorectal Cancer
- FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
- Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-glutamate (18F-FSPG) for PET/CT Imaging in Patients with Newly Diagnosed and Recurrent Prostate Cancer
- Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs
- Boramino acid as a marker for amino acid transporters